{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:23Z","timestamp":1789597703024,"version":"build-2803163510"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2352820","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:32:08Z","timestamp":1715070728000},"page":"766-776","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States"],"prefix":"10.1080","volume":"27","author":[{"given":"Matthew","family":"Matasar","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sanchez Alvarez","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4976-904X","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Paris\u00e9","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7403-3611","authenticated-orcid":false,"given":"Eric","family":"Zuk","sequence":"additional","affiliation":[{"name":"Medicus Economics LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3975-508X","authenticated-orcid":false,"given":"Danilo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6964-4735","authenticated-orcid":false,"given":"Sheila","family":"Shapouri","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Kim","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-430X","authenticated-orcid":false,"given":"Shih-Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"e_1_3_10_2_1","unstructured":"National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ)\u2013health professional version. [cited 2022 Dec 6]. Available from: https:\/\/www.cancer.gov\/types\/lymphoma\/hp\/adult-nhl-treatment-pdq."},{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25696"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3501-8"},{"key":"e_1_3_10_6_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. [cited 2022 Dec 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_10_7_1","unstructured":"Genentech Inc. LUNSUMIO (mosunetuzumab-axgb): highlights of prescribing information. [cited 2023 Jan 3]. Available from: https:\/\/www.gene.com\/download\/pdf\/lunsumio_prescribing.pdf"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00845-x"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1489254"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.010"},{"key":"e_1_3_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2254640"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186548"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2290832"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.003"},{"issue":"2","key":"e_1_3_10_17_1","first-page":"1","article-title":"United States life tables, 2020","volume":"71","author":"Arias E","year":"2022","unstructured":"Arias E, Xu J, Tejada-Vera B, et\u00a0al. United States life tables, 2020. Natl Vital Stat Rep. 2022;71(2):1\u201318.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182244"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016747"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00478"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_10_24_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas V.2.2022. \u00a9 National Comprehensive Cancer Network Inc. 2022. All rights reserved. [cited 2022 Mar 21]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159640"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.09.007"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12357"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_10_29_1","volume-title":"NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data. Report by the decision support unit","author":"Latimer N.","year":"2011","unstructured":"Latimer N. NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data. Report by the decision support unit. Sheffield, UK: School of Health and Related Research; 2011 (last updated March 2013)."},{"key":"e_1_3_10_30_1","unstructured":"AnalySource\u00ae. Reprinted with permission by First Databank Inc. All rights reserved; \u00a9 2023 [cited 2023 Mar 10]. Available from: https:\/\/www.analysource.com\/"},{"key":"e_1_3_10_31_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule; 2022. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview."},{"key":"e_1_3_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01358-y"},{"key":"e_1_3_10_33_1","unstructured":"Centers for Medicare & Medicaid Services. Clinical diagnostic laboratory fee schedule; 2022. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files."},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0057"},{"key":"e_1_3_10_35_1","unstructured":"Kite Pharma Inc. YESCARTA: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"e_1_3_10_36_1","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel): highlights of prescribing information. [cited 2022 Jun 1]. Available from: https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"e_1_3_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005588"},{"key":"e_1_3_10_38_1","unstructured":"Genentech Inc. GAZYVA (obinutuzumab): highlights of prescribing information. [cited 2022 Apr 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125486s029lbl.pdf."},{"key":"e_1_3_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)63491-2"},{"key":"e_1_3_10_41_1","first-page":"578","article-title":"Utility values for patients with indolent non-Hodgkin lymphoma (INHL) in top five European countries (EU-5)","volume":"1","author":"Cognet M","year":"2015","unstructured":"Cognet M, Taieb V, Bec M, et\u00a0al. Utility values for patients with indolent non-Hodgkin lymphoma (INHL) in top five European countries (EU-5). Haematologica. 2015;1:578.","journal-title":"Haematologica"},{"key":"e_1_3_10_42_1","unstructured":"United States Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care (CUSR0000SAM); 2022 [cited 2022 Dec 5]. Available from: https:\/\/www.bls.gov\/data\/."},{"key":"e_1_3_10_43_1","unstructured":"Genentech Inc. RITUXAN (rituximab) injection: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf"},{"key":"e_1_3_10_44_1","unstructured":"Teva Pharmaceuticals USA Inc. BENDEKA: highlights of prescribing information. [cited 2022 Apr 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208194s024lbl.pdf"},{"key":"e_1_3_10_45_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Management of Immunotherapy-Related Toxicities V.1.2022. \u00a9 National Comprehensive Cancer Network Inc. 2022. All rights reserved. [cited 2022 May 3]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_10_46_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas V.1.2024. \u00a9 National Comprehensive Cancer Network Inc. 2024. All rights reserved. [cited 2024 Jan 23]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00204-z"},{"key":"e_1_3_10_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2436.2436"},{"key":"e_1_3_10_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"e_1_3_10_50_1","volume-title":"Final draft guidance: glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [TA927]","author":"National institute for Health and Care Excellence","year":"2023","unstructured":"National institute for Health and Care Excellence. Final draft guidance: glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [TA927]. 17 October 2023 ed. London, UK: national institute for Health and Care Excellence; 2023."},{"key":"e_1_3_10_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_3_10_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177626"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2352820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:42:46Z","timestamp":1772779366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2352820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2352820"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2352820","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}